Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 13
2015 57
2016 70
2017 66
2018 74
2019 60
2020 72
2021 56
2022 65
2023 46
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

483 results

Results by year

Filters applied: . Clear all
Page 1
The argument for using imatinib in CML.
Claudiani S, Apperley JF. Claudiani S, et al. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):161-167. doi: 10.1182/asheducation-2018.1.161. Hematology Am Soc Hematol Educ Program. 2018. PMID: 30504305 Free PMC article. Review.
Imatinib mesylate-induced acute hepatotoxicity.
Frikha I, Fakhfakh Y, Sahnoun R, Chtourou L, Medhaffar M, Elloumi M. Frikha I, et al. J Oncol Pharm Pract. 2023 Dec;29(8):2027-2030. doi: 10.1177/10781552231188307. Epub 2023 Jul 18. J Oncol Pharm Pract. 2023. PMID: 37464887
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators. Hochhaus A, et al. N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324. N Engl J Med. 2017. PMID: 28273028 Free PMC article. Clinical Trial.
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
Bauer S, Jones RL, Blay JY, Gelderblom H, George S, Schöffski P, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Su Y, Meade J, Wang T, Sherman ML, Ruiz-Soto R, Heinrich MC. Bauer S, et al. J Clin Oncol. 2022 Dec 1;40(34):3918-3928. doi: 10.1200/JCO.22.00294. Epub 2022 Aug 10. J Clin Oncol. 2022. PMID: 35947817 Free PMC article. Clinical Trial.
Imatinib Mesylate Induced Erythroderma.
Lunge S, Bhise R. Lunge S, et al. J Assoc Physicians India. 2018 Dec;66(12):79-80. J Assoc Physicians India. 2018. PMID: 31313559
483 results